Santen Pharmaceutical Company Top Insiders
| SNPHF Stock | USD 10.15 0.09 0.88% |
Santen Pharmaceutical employs about 4.3 K people. The company is managed by 11 executives with a total tenure of roughly 24 years, averaging almost 2.0 years of service per executive, having 392.27 employees per reported executive. Examination of Santen Pharmaceutical's management performance can provide insight into the company performance.
| Satoshi Suzuki Director Executive Officer, Chief Director of Planning |
| Nobuko Kato Insider Chief Officer |
Santen |
Santen Pharmaceutical Management Team Effectiveness
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Santen Pharmaceutical Workforce Comparison
Santen Pharmaceutical Co is currently regarded as top stock in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is at this time estimated at about 119,047. Santen Pharmaceutical holds roughly 4,315 in number of employees claiming about 4% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of (0.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Santen Pharmaceutical Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Santen Pharmaceutical Price Series Summation is a cross summation of Santen Pharmaceutical price series and its benchmark/peer.
Santen Pharmaceutical Notable Stakeholders
A Santen Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Santen Pharmaceutical often face trade-offs trying to please all of them. Santen Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Santen Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kazuo Koshiji | CFO, Head of Fin. Division and Sr. Corporate Officer | Profile | |
| Satoshi Suzuki | Executive Officer, Chief Director of Planning | Profile | |
| Takeshi Ito | Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | Profile | |
| Kenji Morishima | Executive Officer, Chief Director of Human Resources & Organization Development and CSR | Profile | |
| Nobuko Kato | Chief Officer | Profile | |
| Mika Masunari | G Officer | Profile | |
| Nikolas Tripodis | Chief Officer | Profile | |
| Kaori Itagaki | Gen Group | Profile | |
| Shinichi Teramachi | Head Officer | Profile | |
| Ippei Kurihara | Japan Department | Profile | |
| Minori Hara | Chief Officer | Profile |
About Santen Pharmaceutical Management Performance
The success or failure of an entity such as Santen Pharmaceutical often depends on how effective the management is. Santen Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Santen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Santen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people.
Santen Pharmaceutical Workforce Analysis
Traditionally, organizations such as Santen Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Santen Pharmaceutical within its industry.Santen Pharmaceutical Manpower Efficiency
Return on Santen Pharmaceutical Manpower
| Revenue Per Employee | 61.7M | |
| Revenue Per Executive | 24.2B | |
| Net Income Per Employee | 6.3M | |
| Net Income Per Executive | 2.5B | |
| Working Capital Per Employee | 24.6M | |
| Working Capital Per Executive | 9.7B |
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |